Our latest insights report focuses on Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder with significant implications for both lung and liver health. AATD arises from a deficiency of the alpha-1 antitrypsin (AAT) protein, which safeguards the lungs from inflammation and damage. With this protein in short supply, the lungs become vulnerable to conditions like emphysema and chronic obstructive pulmonary disease (COPD), with symptoms that often include chronic cough, shortness of breath, and wheezing. Environmental exposures, including smoking, air pollution, and occupational dust, can significantly accelerate lung damage in individuals with low AAT levels. Beyond the lungs, AATD can also lead to liver scarring, known as cirrhosis, as the misfolded AAT protein accumulates in liver cells rather than entering the bloodstream.
Because AATD symptoms overlap with more common respiratory conditions, many individuals remain undiagnosed or receive a delayed diagnosis, sometimes by years. This diagnostic gap makes genetic testing a critical step in identifying affected individuals and connecting them with appropriate care or research opportunities.
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that primarily affects lung and liver health.
The condition is caused by a deficiency in the alpha-1 antitrypsin protein, which is essential for protecting lungs from inflammatory damage.
Low levels of this protein increase the risk of developing emphysema and chronic obstructive pulmonary disease (COPD).
The insights report covers global prevalence, diagnostic challenges, and the current landscape of genetic research.
AATD prevalence: Its impact on global health.
Diagnostic hurdles: The challenges in identifying the condition early.
Clinical landscape: Available treatments and ongoing genetic research.